Navigation Links
Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD
Date:2/11/2010

SINGAPORE, Feb. 11 /PRNewswire-Asia/ -- The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

The French research team was led by Prof. Michel Lazdunski, world-renowned specialist of pharmacology.

The data demonstrates NeuroAiD effects on decreasing cognitive deficits, preventing death of threatened neuronal tissues and improving functional outcomes by repairing and restoring neuronal circuits. This is fully consistent with clinical observations of NeuroAiD efficacy as a post stroke treatment.

NeuroAiD treatment increases survival rate, reduces infarct volume, prevents neuronal death and drastically decreases functional deficits in rodents' stroke models. The data also shows NeuroAiD effectiveness in reducing stroke severity when administrated preventively.

The results show that NeuroAiD triggers the synthesis of Brain Derived Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the development of new neuronal circuits of information.

Previous trials and clinical reports conducted in Asia have already demonstrated high levels of NeuroAiD safety and efficacy in improving stroke rehabilitation, even when taken several months after stroke onset. NeuroAiD Stroke Treatment is already available in many countries in Asia and in the Middle East for stroke survivors. New clinical assessments will be conducted in France and Europe shortly on stroke recovery.

David Picard, CEO of Moleac, said "We are extremely enthusiastic and proud to see these data published. It is a strong validation of our research of active ingredients in NeuroAiD as well as of our efforts towards continuous optimization of its formula. These results pave the way for new indications of NeuroAiD beyond stroke recovery such as prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatment in this under-served therapeutic area."

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide. http://www.moleac.net

About NeuroAiD

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries. http://www.neuroaid.com

    Contact details:

     Kasia Kaminska
     Tel: +65-64789432
     Kasia.kaminska@moleac.net

SOURCE Moleac

RELATED LINKS
http://www.moleac.net
http://www.neuroaid.com

'/>"/>

SOURCE Moleac
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
2. Moleac Launches NeuroAid10(TM) in the United States
3. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
4. Kinexus Announces the Launch of a New Protein Kinase Microarray
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions
10. Angiotech Pharmaceuticals Announces Conference Call and Webcast
11. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  In Atlanta, it seems everyone has a chance to ... create an expressive and dynamic community unlike any other. The ... to it. With their newest salon in ... to carry on that tradition with a unique, fresh approach ... salon is the newest of 13 nationwide locations, each of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a published evaluation of multiple immunoassay-based threat detection technologies by researchers from ... PathSensors’ CANARY® biosensor threat detection technology was found to have the best ...
(Date:2/23/2017)... ... ... Today, researchers can fast-track sample collection and analysis for ... or SNPs of interest) using one, easy-to-collect saliva sample. With the addition of ... and other relevant biomarkers can be extensively studied through a non-invasive sample type. ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
(Date:2/1/2017)... February 1, 2017 IDTechEx Research, a leading ... technology, announces the availability of a new report, Sensors for ... Continue Reading ... ... collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and ...
Breaking Biology News(10 mins):